|
Consolidated Condensed Balance Sheets (USD $) In Millions, unless otherwise specified
|
Mar. 31, 2015
|
Dec. 31, 2014
|
| Current Assets |
|
|
| Cash and cash equivalents |
$ 3,064.8 |
$ 3,871.6 |
| Short-term investments |
1,075.0 |
955.4 |
| Accounts receivable, net of allowances of $49.9 (2015) and $55.0 (2014) |
3,142.5 |
3,234.6 |
| Other receivables |
683.2 |
566.7 |
| Inventories |
2,980.2 |
2,740.0 |
| Prepaid expenses and other |
797.0 |
811.5 |
| Total current assets |
11,742.7 |
12,179.8 |
| Other Assets |
|
|
| Restricted cash |
0 |
5,405.6 |
| Investments |
4,576.5 |
4,568.9 |
| Goodwill |
3,946.9 |
1,758.1 |
| Other intangibles, net |
4,947.7 |
2,884.2 |
| Sundry |
2,489.4 |
2,417.7 |
| Total other assets |
15,960.5 |
17,034.5 |
| Property and Equipment |
|
|
| Land, buildings, equipment, and construction in progress |
16,213.3 |
16,029.3 |
| Accumulated depreciation |
(8,262.6) |
(8,065.4) |
| Property and equipment, net |
7,950.7 |
7,963.9 |
| Total assets |
35,653.9 |
37,178.2 |
| Current Liabilities |
|
|
| Short-term borrowings and current maturities of long-term debt |
805.4 |
2,688.7 |
| Accounts payable |
1,179.6 |
1,128.1 |
| Employee compensation |
518.7 |
759.0 |
| Sales rebates and discounts |
2,025.7 |
2,068.8 |
| Dividends payable |
0 |
530.3 |
| Deferred income taxes |
1,296.7 |
1,466.5 |
| Other current liabilities |
2,516.8 |
2,566.1 |
| Total current liabilities |
8,342.9 |
11,207.5 |
| Other Liabilities |
|
|
| Long-term debt |
7,415.3 |
5,367.7 |
| Accrued retirement benefits |
2,520.8 |
2,562.9 |
| Long-term income taxes payable |
954.0 |
998.5 |
| Other noncurrent liabilities |
1,474.4 |
1,653.5 |
| Total other liabilities |
12,364.5 |
10,582.6 |
| Eli Lilly and Company Shareholders' Equity |
|
|
| Common stock |
694.1 |
694.6 |
| Additional paid-in capital |
5,279.6 |
5,292.3 |
| Retained earnings |
16,706.8 |
16,482.7 |
| Employee benefit trust |
(3,013.2) |
(3,013.2) |
| Accumulated other comprehensive loss |
(4,657.5) |
(3,991.8) |
| Cost of common stock in treasury |
(90.0) |
(91.4) |
| Total Eli Lilly and Company shareholders' equity |
14,919.8 |
15,373.2 |
| Noncontrolling interests |
26.7 |
14.9 |
| Total equity |
14,946.5 |
15,388.1 |
| Total liabilities and equity |
$ 35,653.9 |
$ 37,178.2 |